Equity eroded 66% to NZ$0.6m on continued losses and a NZ$0.4m revenue base

Total assets contracted 39.4% to NZ$1.9m, with inventories down 47.8% to NZ$0.4m and gross borrowings unchanged at NZ$0.1m.

Revenue moved from NZ$0.6m to NZ$0.4m (the period-on-period growth rate carries a basis-discontinuity caveat and is not stated here as a specific figure). Loss before tax narrowed from –NZ$0.9m to –NZ$0.7m, and NPAT moved from –NZ$0.5m to –NZ$0.4m; both growth rates carry the same basis caveat.

Gross margin swung from –38.2% to +7.5%, a 4,570bp improvement reflecting the absence of last year's inventory impairment. Operating cash outflow narrowed from –NZ$0.5m to –NZ$0.1m, and closing cash sits at NZ$0.014m, up from NZ$0.003m.

The NZ$1.1m equity decline exceeds the parent-attributable loss of NZ$0.4m and even the total NZ$0.7m loss before tax, leaving a residual gap not addressed in the supplied excerpts. For an issuer with only NZ$0.6m of remaining equity, the gap matters because it directly affects how many further loss-making years the balance sheet can absorb without dilution or external capital.

Cash runway is the binding constraint. Closing cash of NZ$14k against an annual operating outflow of NZ$126k implies roughly six weeks of headroom at the run rate, with no undrawn facility disclosed and borrowings flat at NZ$53k. The operating cash improvement is real in direction but the absolute level still consumes the entire cash buffer in a fraction of a year.

Gross margin turned positive but on a shrinking base. A 7.5% gross margin versus –38.2% is the clearest sign of underlying cost discipline, yet it is being struck on revenue of NZ$0.4m. Unit economics improving while scale contracts does not, on its own, produce a path to operating breakeven.

The interim release noted that AFC "encountered continuous challenges due to COVID-19 spread, NZ border closure and the slow recovery of overseas sales," and the prior-year commentary cited the same drivers — so the release describes pressure that the company says is ongoing rather than resolving.

The half-year context shows HY22 revenue of NZ$0.111m against the full-year NZ$0.415m, implying second-half revenue of roughly NZ$0.30m, the stronger half. That shape supports the idea that activity picked up later in the year, but the release does not provide a forward order book, pricing commitment, or capital plan that would let the read extend beyond what FY22 already shows.

Inventories fell NZ$0.3m and receivable days dropped from 102.5 to 7.9, both of which release cash that does not recur. The gross margin swing is similarly explained by the prior-year base: FY21 carried the inventory impairment that pushed gross margin to –38.2%, so its absence in FY22 produces an arithmetic recovery rather than a demonstrated pricing or cost step-up.

Inventory days moved the other way, from 275 to 335, which is consistent with sales falling faster than stock-on-hand and is a forward risk to gross margin if further write-downs are needed. Capex was negligible at NZ$4k, so there has been no investment-led drag on cash but equally no asset reinforcement. A small PPE impairment of NZ$28k was booked. Taken together, the FY22 numbers look better than FY21 because FY21 carried specific charges, not because the operating engine has scaled.

This briefing cannot assess going-concern status, available capital pathways, or any post-balance-date events, because the supplied release excerpts do not disclose them.